drugset / Trial / NCT00113893
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of oral SCIO-469 in patients with myelodysplastic syndromes. SCIO-469 belongs to a new class of treatments that inhibit expression and activity of cytokines that play a role in the progression of MDS.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TALMAPIMOD | Small molecule | 30 mg | Oral |
| Subject | TALMAPIMOD | Small molecule | 60 mg | Oral |
| Subject | TALMAPIMOD | Small molecule | 90 mg | Oral |
| Subject | TALMAPIMOD | Small molecule | 120 mg | Oral |